The clinical impact and cancer risks for individuals with pathogenic variants in BRCA1/2 are well studied.8 Likewise, medical management guidelines have been established and are frequently updated.3–5 These guidelines also address high- and moderate-risk genes such as TP53 and PTEN. 3,9,10 Although medical management guidelines exist for many other genes such as PALB2, CHEK2, and ATM, no defined testing criteria have been established. This evidence concerns the gene CHEK2 and cancer.